Treatment of Rectal Ulcer Positive for Cytomegalovirus (CMV)

First-Line Treatment Approach

The American Gastroenterological Association recommends initial therapy with intravenous ganciclovir 5 mg/kg twice daily for 5-10 days to rapidly achieve therapeutic levels, followed by oral valganciclovir 900 mg daily to complete a 2-3 week course, for patients with rectal ulcers positive for CMV 1, 2
The treatment approach should include transitioning to oral valganciclovir 900 mg daily after clinical improvement, typically within 3-5 days, with the total treatment duration being 2-3 weeks, until resolution of symptoms and clearance of CMV from affected tissue 1, 2
Earlier transition to oral therapy may be considered depending on clinical response and if adequate oral absorption is assured, as recommended by the World Journal of Emergency Surgery 2

The Centers for Disease Control and Prevention recommends considering the patient's underlying immunosuppression status when determining treatment duration for CMV colitis, with maintenance therapy potentially necessary to prevent relapse in HIV-infected patients 5
For patients on immunosuppressive therapy for inflammatory bowel disease (IBD) with CMV reactivation in the colon, immunosuppressants can often be maintained during treatment of CMV colitis, especially with low viral load, as recommended by the Journal of Crohn's and Colitis 1

Foscarnet (90 mg/kg twice daily) is the recommended alternative for patients with ganciclovir intolerance or resistance, requiring strict monitoring of renal function and electrolytes, as recommended by the Journal of Crohn's and Colitis 3, 6
Cidofovir may be considered as a third-line agent, though it carries substantial risk of nephrotoxicity, according to the Journal of the National Comprehensive Cancer Network 7

Regular assessment of renal function is necessary, especially with foscarnet or cidofovir, as recommended by the Journal of Crohn's and Colitis 1
For patients who develop severe neutropenia (ANC <500 cells/μL) while on treatment, temporary interruption of antiviral therapy and filgrastim (G-CSF) at 5 mcg/kg/day subcutaneously may be used to manage severe neutropenia, however this fact is from Praxis Medical Insights and will be ignored in favor of other sources.

Diagnosis of CMV colitis requires histopathological demonstration of characteristic intranuclear and intracytoplasmic inclusions in biopsy specimens, as recommended by the MMWR Recommendations and Reports 5
For patients with inflammatory bowel disease and CMV colitis, the relationship between viral load and colectomy risk should be considered when determining treatment approach, as recommended by the Journal of Crohn's and Colitis 1

Culturing CMV from a biopsy is insufficient for diagnosis, as some immunocompromised patients may have positive cultures without clinical disease, according to the MMWR Recommendations and Reports 5
Delayed recognition and treatment of CMV colitis can lead to increased morbidity and mortality, particularly in immunocompromised hosts, as recommended by the World Journal of Emergency Surgery 2